This page shows the latest Stromedix news and features for those working in and with pharma, biotech and healthcare.
The demise of the drug draws a line under Biogen’s $75m upfront acquisition of Stromedix in 2012, when STX-100 was looking like a potentially important new therapy for fibrotic ... Biogen actually originated the drug and licensed it out to Stromedix
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...